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Background: The metabolic effect of intratumor cholesteryl ester (CE) in breast cancer remains poorly understood.
The objective was to analyze the relationship between intratumor CE content and clinicopathological variables in
human breast carcinomas.
Methods: We classified 30 breast carcinoma samples into three subgroups: 10 luminal-A tumors (ER+/PR+/Her2-),
10 Her-2 tumors (ER-/PR-/Her2+), and 10 triple negative (TN) tumors (ER-/PR-/Her2-). We analyzed intratumor neutral
CE, free cholesterol (FC) and triglyceride (TG) content by thin layer chromatography after lipid extraction. RNA and
protein levels of lipid metabolism and invasion mediators were analyzed by real time PCR and Western blot
analysis.
Results: Group-wise comparisons, linear regression and logistic regression models showed a close association
between CE-rich tumors and higher histologic grade, Ki-67 and tumor necrosis. CE-rich tumors displayed higher
mRNA and protein levels of low-density lipoprotein receptor (LDLR) and scavenger receptor class B member 1
(SCARB1). An increased expression of acetyl-Coenzyme A acetyltransferase 1 (ACAT1) in CE-rich tumors was also
reported.
Conclusions: Intratumor CE accumulation is intimately linked to proliferation and aggressive potential of breast
cancer tumors. Our data support the link between intratumor CE content and poor clinical outcome and open the
door to new antitumor interventions.
Keywords: ACAT1, Breast cancer, CD36, Cholesteryl ester, LDL receptor, SCARB1Background
The homeostasis of lipids is deregulated in several tu-
mors [1, 2] including breast cancer [3, 4]. The risk of
breast cancer increases in association with high fat diets,
overweight, obesity, and type 2 diabetes, conditions
characterized by an anomalous lipid profile [5–7]. Plasma
levels of total cholesterol, low-density lipoprotein (LDL)
and triglycerides (TG) are frequently higher, and high* Correspondence: cllorente@csic-iccc.org
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unless otherwise stated.density lipoproteins (HDL) lower, in patients with breast
cancer [8, 9]. The expression of lipid metabolism genes is
also changed in breast tumors compared to the normal
adjacent tissue [10]. Dyslipidemia favors mammary tumor
growth and metastasis in in vivo models [11], and LDL and
HDL stimulate proliferation and migration in in vitro breast
tumor cell models [12–15]. Taken together, these results
show a close relationship between the deregulation of lipid
homeostasis and breast cancer.
Plasma lipoproteins are a source of fatty acids (FA)
and cholesteryl esters (CE) for tumor cells. FA oxidation
is the main source of energy for prostate and pancreatic
tumors [16, 17]. Availability of intratumoral CE reducesn Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical and pathological characteristics of patients and
tumor samples
Variables N = 30
Age (years) 62.5 (48.8-76.0)
Clinicopathological parameters
Breast carcinoma type
Luminal-A (%) 10 (33)
Her-2 (%) 10 (33)
TN (%) 10 (33)
Histologic types
Invasive ductal carcinoma (%) 26 (87)
Medullary carcinoma (%) 2 (7)
Papillary carcinoma (%) 1 (3)
Mixed carcinoma (%) 1 (3)
Nottingham combined histologic grade
Grade I (%) 6 (20)
Grade II (%) 4 (13)
Grade III (%) 20 (67)
TNM staging
Stage IA (%) 7 (23)
Stage IIA (%) 14 (47)
Stage IIB (%) 4 (13)
Stage IIIA (%) 2 (7)
Stage IIIB (%) 1 (3)
Stage IV (%) 1 (3)
Unknown (%) 1 (3)
Tumor size (cm) 3.00 (2.00-4.00)
Lymph node affected (%) 10 (33)
Vascular invasion (%) 4 (13)
Tumor necrosis (%) 12 (40)
Mean Ki-67 (%) 20 (5–53)
Ki-67 over 20 (%) 15 (50)
Other conditions
Dyslipidemia (%) 11 (38)
Menopause (%) 15 (50)
Intratumor lipid parameters
CE (μg/mg protein) 3.14 (1.45-4.65)
TG (μg/mg protein) 5.91 (2.87-13.95)
Free Chl (μg/mg protein) 4.97 (4.47-5.50)
Data are presented as medians (interquartile ranges) for continuous variables
and as frequencies (percentages) for categorical variables
CE: Cholesteryl Esters; Free Chl: Free Cholesterol; Her-2: Human Epidermal
Growth Factor Receptor 2; TG: Triglycerides; TN: Triple Negative
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induces lipid raft formation and alters tumor cell sig-
naling, essential processes for tumor proliferation, in-
vasiveness and survival [18–20]. In concordance with
these data, the inhibition of CE synthesis has antican-
cer effects [21, 22].
Breast tumor subtypes represent different molecular
entities that show great heterogeneity in their tumori-
genesis, aggressiveness and malignancy and a significant
disparity in clinical outcomes and management [23–27].
Furthermore, most investigations about deregulated lipid
metabolism in breast neoplasms have been performed
in vitro and animal models rather than in human sam-
ples. This makes it difficult to extrapolate results for
clinical practice. Complementary knowledge based on
translational approaches is thus required to improve
diagnosis and treatment of breast cancer. We hypothe-
sized that intratumor CE levels are associated with clini-
copathological variables in human breast carcinomas.
The objective of this study was thus to analyze the rela-
tionship between intratumor CE content, lipid metabol-
ism mediators, invasion markers, and clinicopathological
parameters.
Material and Methods
Patient and tumor samples
The clinical-pathological features of patients and tumor
samples are summarized in Table 1. Thirty tumor sam-
ples were selected retrospectively (from May 2006 to
November 2012) from the Tumor Tissue Bank in the
Pathology Department at Hospital Santa Creu i Sant
Pau, Barcelona, Spain. Tumor samples were classified in
three subgroups: 10 cases were Luminal-A tumors (ER
+/PR+/Her2-), 10 Her-2 tumors (ER-/PR-/Her2+) and
10 TN tumors (ER-/PR-/Her2-). For this comparative
clinicopathological and molecular study, we selected a
similar number of each subtype of breast carcinomas.
Exclusion criteria were patients with mutations in
BRCA1 and BRCA2 genes. Patients were staged accord-
ing to the TNM staging system and tumors were proc-
essed and studied according to the standard protocols
[28, 29]. The Ki-67 index was also evaluated by immu-
nohistochemistry. Patients’ medical history and clinical
evaluation were fully reviewed. The presence of dyslipid-
emia and menopause was based on explicit diagnosis
in the medical history, assuming that, to diagnose the
condition, clinicians have followed the criteria admit-
ted to each time. Patients were treated according to
our institution guidelines, essentially first treatment
was surgery for patients with stages I and II, followed
by adjuvant chemotherapy, endocrine therapy and
radiotherapy when indicated.
This study was conducted according to the Declaration
of Helsinki principles, with approval from the ClinicalResearch Ethics Committee at Institut d’Investigacions
Biomèdiques Sant Pau. Written informed consent was ob-
tained from all patients
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Tumor tissue samples were obtained from surgical spec-
imens, mastectomy or lumpectomy, rapidly embedded in
OCT (Tissue-Tek, Sakura, Europe, Alphen den Rijn, The
Netherlands) and frozen using a histobath (Thermo
Shandon, Pittsburgh, PA, USA). A macrodisecction of
the samples was performed to remove fatty tissue and
exclusively collect tumoral tissue. Immunohistochemis-
try was carried out using the EnVision Flex™ detection
system (Dako/Agilent Technologies; Carpinteria, CA),
following the manufacturer´s instructions.
RNA extraction and cDNA synthesis
Total RNA was extracted from frozen tumoral tissue
using TriPure isolation reagent (Roche Molecular Bio-
chemicals) and the RNeasy mini kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Extracted RNA was eluted in 25 μL of nucleases-free
water. RNA yield and quality were assessed by agarose
electrophoresis and spectrophotometry, and then storedTable 2 Mediators of tumor lipid homeostasis and invasion
Marker
Tumor Lipid Homeostasis
Lipid internalization
Low density lipoprotein receptor-related protein 1
Cluster of Differentiation 36
Very low-density lipoprotein receptor
Low-density lipoprotein receptor
Scavenger receptor class B member 1
Lipid efflux
ATP-binding cassette transporter
Cholesterol synthesis
3-hydroxy-3-methyl-glutaryl-CoA reductase
Fatty acid synthesis
Fatty acid synthase
Cholesterol esterification
Acetyl-Coenzyme A acetyltransferase 1
Cholesterol management
Caveolin-1
Liver X receptor α
Sterol regulatory element-binding transcription factor 1
Sterol regulatory element-binding transcription factor 2
Tumor Invasion
Matrix metalloproteinase-2
Matrix metalloproteinase-9
Tissue inhibitor of metalloproteinase 1
Cathepsin Sat −80 °C until use. RNA was digested with DNase I
(Invitrogen). One μg of total RNA was used for cDNA
synthesis according to the protocol provided with the
High Capacity cDNA Reverse Transcription kit (Applied
Biosystems, Foster City, CA, USA). Recombinant RNasin
Ribonuclease Inhibitor (Applied Biosystems) was added
to prevent RNase-mediated degradation. The cDNA was
also stored at –20C.
Gene expression analyses by RT-PCR
The expression of different genes involved in lipid me-
tabolism and tumor invasion was analyzed at mRNA
level by quantitative real-time reverse transcriptase-
polymerase chain reaction (q-RT-PCR). Specific primer
and fluorescent TaqMan probes were selected within a
list of predesigned assays (Table 2). 18srRNA (4319413E)
was used as a housekeeping gene. We mixed 5 μl of
single-stranded cDNA (equivalent to 100 ng of total
RNA) with 1 μl of 20x TaqMan Gene Expression Assays
for each Assay-on-Demand, 10 μl of TaqMan UniversalAbbreviation Probe ID
LRP1 Hs00233899_m1
CD36
VLDLR Hs01045922_m1
LDLR Hs00181192_m1
Gene:SCARB1
Protein: SR-BI
ABCA1 Hs01059118_m1
HMG-CoAR Hs00168352_m1
FASN Hs01005622_m1
ACAT1 Hs00608002_m1
CAV1 Hs00971716_m1
LXR-α Hs00172885_m1
SREBP1 Hs00231674_m1
SREBP2 Hs00190237_m1
MMP-2 Hs00234422_m1
MMP-9 Hs00234579_m1
TIMP1 Hs01092511_m1
CTSS Hs00175407_m1
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gentle mixing, the mixture was transferred into a real-
time PCR microplate. The Real-time PCR microplate
was sealed, centrifuged, and placed in the sample block
of an Applied Biosystems 7300 Real Time PCR System
(Applied Biosystems). The thermal cycling conditions
were 2 min at 50 °C and 10 min at 95 °C, followed by
40 cycles of 15 s at 95 °C and 1 min at 60 °C. Expression
levels were measured in triplicate. The threshold cycle
(Ct) values were normalized to the housekeeping gene.
Western blotting
Total protein was extracted from tumoral frozen tissue
using TriPure isolation reagent (Roche Molecular Bio-
chemicals). Proteins were analyzed by Western blot ana-
lysis under non-reducing (LRP1 and VLDLR) and
reduced (LDLR, SR-BI, CTSS and MMP9) conditions on
polyacrylamide gels for SDS-PAGE. The samples were
electrotransferred to nitrocellulose, and the membranes
were saturated at room temperature for 1 hour in TTBS
(20 mM Tris–HCl pH 7.5, 500 mM NaCl, 0.01 % Tween
20, and 5 % non-fat milk). Western blot analysis was
performed with specific monoclonal antibodies against
LRP1 (10R-L107c, Fitzgerald), VLDLR (sc-18824, SantaTable 3 Clinical and pathological characteristics according to breast
Variables Luminal-A
N = 10
Age (years) 66.5 (46.8-85.3)
Clinicopathological parameters
Nottingham combined histologic grade
Grade I (%) 5 (50)
Grade II (%) 4 (40)
Grade III (%) 1 (10)
TNM Stage
Stage I-II (%) 9 (90)
Stage III-IV (%) 1 (10)
Unknown (%) 0 (10)
Tumor size (cm) 2.25 (1.88-3.62)
Lymph node affected (%) 4 (40)
Vascular invasion (%) 1 (10)
Tumor necrosis (%) 1 (10)
Ki-67 (%) 5.00 (4.50-7.75)
Ki-67 over 20 (%) 0 (0)
Other conditions
Dyslipidemia (%) 2 (20)
Menopause (%) 5 (50)
Data are presented as medians (interquartile ranges) for continuous variables and a
p-values by Krusall-Wallis test, Pearson´s Chi square test or Fisher’s exact test when
*Statistically significant
For continuous variables U Mann–Whitney test was performed when Krusall-Wallis
CE: Cholesteryl Esters; Free Chl: Free Cholesterol; Her-2: Human Epidermal Growth FCruz Biotechnology), LDLR (ab52818, Abcam), SR-BI
(sc-67098, Santa Cruz Biotechnology), CTSS (sc-271619,
Santa Cruz Biotechnology), and MMP9 (AB805, Chemi-
con International). Equal protein loading in each lane
was verified by staining filters with Pounceau. A refer-
ence sample was applied in all blots and the value of the
reference sample was used to normalize the other sam-
ples of the same blot.
Lipid extraction and semi-quantitative analysis of
cholesteryl ester, free cholesterol and triglyceride content
of tumor samples
An aliquot of the frozen tumoral tissue was homoge-
nized in NaOH 0.1 M, and CE, TG and free cholesterol
(FC) were partitioned by thin layer chromatography after
lipid extraction as previously described [30, 31]. The dif-
ferent concentrations of standards (a mixture of cho-
lesterol, cholesterol palmitate and triglycerides) were
applied to each plate. The chromatographic developing
solution was heptane/diethylether/acetic acid (74:21:4,
vol/vol/vol). The spots corresponding to CE, TG and FC
were quantified by densitometry against the standard
curve of cholesterol palmitate, triglycerides and choles-
terol, respectively, using a computing densitometer.carcinoma type
Her-2 TN
N = 10 N = 10 p-value
54.0 (49.8-63.0) 68.5 (50.8-76.0) 0.477
<0.001*
0 (0) 1 (10)
0 (0) 0 (0)
10 (100) 9 (90)
0.779
8 (80) 8 (80)
1 (10) 2 (20)
1 (10) 0 (10)
2.75 (1.73-4.12) 3.25 (2.57-4.25) 0.349
3 (30) 3 (30) 0.861
2 (20) 1 (10) 0.749
6 (60) 5 (50) 0.054
30.00 (12.50-42.50)a 65.00 (21.25-82.50) b 0.001*
7 (70) 8 (80) 0.001*
1 (10) 8 (80) 0.003*
6 (60) 4 (40) 0.537
s frequencies (percentages) for categorical variables
corresponding
test was significant: aLuminal-Avs.Her-2; bLuminal-Avs. TN; c Her-2vs. TN
actor Receptor 2; TG: Triglycerides; TN: Triple Negative
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Statistical analysis was performed using SPSS 15.0 statis-
tical software (SPSS Inc, Chicago, IL). Descriptive statis-
tics were used to characterize the study population and
to describe the clinicopathological variables. Data are
presented as frequencies (percentages) for categorical
variables, and medians (interquartile ranges) for continu-
ous variables. Categorical variables were compared be-
tween groups using Pearson´s Chi square test or Fisher’sFig. 1 Intratumor cholesteryl ester (CE), triglyceride (TG) and free cholestero
thin layer chromatography showing CE, TG and FC bands in three luminal
(interquartile ranges) of intratumor CE (b), TG (c) and FC (d) content in luminal-A
showing a high content of intratumor vacuoles (asterisk) in Her-2 and TN breexact test as required. Continuous variables were compared
between groups with the Krusall-Wallis test or non-
parametric Mann–Whitney U test for medians, as required.
In comparisons where differences between groups were de-
tected with the Krusall-Wallis test, the Mann–Whitney U
test for medians was used with Bonferroni correction to
test for differences in pairs (0.05/3 = 0.017). Correlations
were performed with Spearman's rank test. Linear regres-
sion analysis was performed to explore the associationl content (FC) in Luminal-A, Her-2 and TN breast tumors. (a) Representative
-A, Her-2 and TN representative tumors. Bar graphs show medians
(n = 10), Her-2 (n = 10) and TN (n = 10) groups. (e), Representative images
ast tumors
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models were developed: unadjusted (model 1) and ad-
justed by age (model 2). Logistic regressions were per-
formed to examine the associations between categorical
clinicopathological parameters and intratumor CE con-
tent. Model 1 was unadjusted. To establish whether the
observed association could be influenced by possible con-
founders, model 2 was adjusted by age and neoadjuvant
therapy. Differences were considered statistically signifi-
cant when p < 0.05.
RESULTS
Clinicopathological findings according to receptor status
Table 3 summarizes clinicopathological characteristics
according to receptor status. Her-2 and TN tumors were
the most prevalent in grade III and Ki-67 over 20 %.
Tumor necrosis was more prevalent in Her-2 and TNTable 4 Clinical and pathological characteristics according to intratu
Variables ControlN = 20
Age (years) 65.5 (49.8-78.3
Clinicopathological parameters
Breast carcinoma type
Luminal-A (%) 10 (50)
Her-2 (%) 6 (30)
TN (%) 4 (20)
Nottingham combined histologic grade
Grade I (%) 6 (30)
Grade II (%) 4 (20)
Grade III (%) 10 (50)
TNM Stage
Stage I-II (%) 17 (85)
Stage III-IV (%) 3 (15)
Unknown (%) 0 (10)
Tumor size (units) 2.40 (1.85-3.87
Lymph node affected (%) 7 (35)
Vascular invasion (%) 2 (10)
Tumor necrosis (%) 4 (20)
Ki-67 (%) 8.50 (5.00-28.7
Ki-67 over 20 (%) 6 (30)
Other conditions
Dyslipidemia (%) 7 (35)
Menopause(%) 11 (55)
Intratumor lipid parameters
CE (μg/mg protein) 2.59 (1.29-3.30
TG (μg/mg protein) 4.31 (2.07-18.7
Free Chl (μg/mg protein) 4.89 (4.24-5.25
Data are presented as medians (interquartile ranges) for continuous variables and a
p-values by Mann–Whitney U test or by Fisher’s exact test. *Statistically significant
CE: Cholesteryl Esters; Free Chl: Free Cholesterol; Her-2: Human Epidermal Growth Fthan in Luminal-A tumors but did not reach statistical
significance (p = 0.054). There were no differences in
TNM stage, tumor size, number of lymph nodes affected
and vascular invasion markers between groups. Con-
cerning other conditions, dyslipidemia was more preva-
lent in patients with TN carcinomas than in those with
Luminal-A or Her-2 tumors.
Thin layer chromatography after lipid extraction
showed that intratumoral CE accumulation was signifi-
cantly higher in Her-2 and TN tumors than in Luminal-
A tumors: Her-2: 3.55 (2.78-7.85) & TN: 5.11 (1.69-6.79
vs. Luminal-A: 1.38 (1.09-3.24) (Fig. 1a and b). In con-
trast, there were no differences in intratumor TG (Fig. 1a
and c) or FC (Fig. 1a and d) content between groups.
Immunhistochemical studies showed the presence of
cytoplasmic vacuoles (asterisks) in Her-2 and TN breast
tumors cells (Fig. 1e).mor cholesteryl esters content tertile
CE-richN = 10 p-value
) 53 (45.5-73.0) 0.267
0.015*
0 (0)
4 (40)
6 (60)
0.024*
0 (0)
0 (0)
10 (100)
0.636
8 (80)
1 (10)
1 (10)
) 3.25 (2.57-4.00) 0.231
3 (30) 0.560
2 (20) 0.407
8 (80) 0.003*
5) 65.00 (37.50-82.50) <0.001*
9 (90) 0.003*
4 (40) 0.466
4 (40) 0.603
) 7.30 (5.94-8.67) <0.001*
0) 7.36-14.38) 0.502
) 5.18 (4.71-6.29) 0.155
s frequencies (percentages) for categorical variables
actor Receptor 2; TG: Triglycerides; TN: Triple Negative
Table 5 Association between intratumor cholesteryl ester
content and Ki-67
B (95 % CI) β p value
Model 1
CE 7.323 (3.981-10-666) 0.662 <0.001*
Model 2
CE + Age 7.353 (3.731-10.975) 0.665 <0.001*
B: Beta; CI: Confidence Interval; β: Standardized betas
Model 1: Unadjusted; Model 2: Adjusted by age
*Statically significant
CE: Cholesteryl Esters
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We analyzed the expression of: a) genes involved in lipid
metabolism including lipid uptake, cholesterol synthesis,
fatty acid synthesis, cholesterol esterification, cholesterol
management and cholesterol efflux; and b) genes in-
volved in tumor invasiveness (Table 2). Real time PCR
results showed that LDLR and ACAT1 expression was
significantly higher in Her-2 than in luminal-A tumors
(Additional file 1: Table S1). No differences between
tumor subtypes were observed in other mediators of
lipid uptake, cholesterol synthesis, fatty acid synthesis,
CE synthesis, cholesterol management, or cholesterol
efflux. No differences were reported in markers of
invasion.
Clinicopathological findings according to intratumor CE
content
To explore the associations between intratumor CE
levels and tumor malignancy, the population was divided
into statistical tertiles of intratumor CE content: tertile
1: 0.16-2.59 (μg/mg protein), tertile 2: 2.60-5.16 (μg/mg
protein), and tertile 3: 5.17-9.92 (μg/mg protein). Tumor
samples in tertile 3 were considered the CE-rich group.
The remaining tissue samples were included in the con-
trol CE group. Table 4 summarizes clinicopathological
characteristics according to intratumor CE levels. Re-
garding receptor status, the highest CE tertile wasTable 6 Association between intratumor cholesteryl esters content
Model 1
OR (95 % CI)
Histologic grade (III vs. I-II) 2.115 (1.134-3.945)
TNM Stage (III-IV vs. I-II) 0.693 (0.332-1.447)
Tumor size >3 cm (%) 1.056 (0.794-1.404)
Lymph node affected 0.811 (0.569-1.158)
Vascular invasion 1.112 (0.723-1.711)
Tumor necrosis 1.718 (1.123-2.630)
Ki-67 over 20 % 1.781 (1.120-2.831)
OR: Odds Ratio. CI: Confidence Interval
Model 1: Unadjusted; Model 2: Adjusted by age and neoadjuvant therapy
*Statically significantexclusively composed of Her-2 (40 %) and TN (60 %)
carcinomas. Luminal-A tumors were all included in the
group with lower CE content. According to histological
grade, all tumors in the highest tertile of CE content
were grade III. Tumor necrosis and Ki-67 were higher in
the CE-rich group than in the control group (80 % vs
20 % and 90 % vs 30 %). Ki-67 levels were higher in tu-
mors of tertile 3 than in tumors of tertiles 1 and 2.
There were no statistically significant differences be-
tween groups in TNM stage, tumor size, number of
lymph nodes affected or vascular invasion markers.
There were no differences according dyslipidemia or
menopause status between groups. There were no dif-
ferences in TG or free cholesterol levels between the
CE-rich group and other groups.
To further explore the relationships between the intra-
tumoral CE accumulation and clinicopathological parame-
ters, we analyzed the association between intratumoral CE
accumulation and the clinicopathological categorical vari-
ables: histologic grade (III vs. I-II), TNM stage (III-IV vs.
I-II), tumor size > 3 cm, lymph node affected, vascular
invasion, tumor necrosis and Ki-67 > 20 %. Logistic re-
gression models showed a direct association between
intratumoral CE accumulation and higher histologic
grade, tumor necrosis and Ki-67 > 20 % (Tables 5 and 6).
To analyze the influence of age on the associations be-
tween the intratumor CE content and clinicopathological
parameters, logistic regressions were adjusted for these
covariables and the association between CE levels and
histologic grade, tumor necrosis and Ki-67 > 20 %,
remained statistically significant (Table 5). No associa-
tions between intratumor CE content and TNM Stage,
tumor size, lymph node affected or vascular invasion
were reported.
Molecular analysis according to intratumor CE content
CE-rich tumors presented higher LDLR (Fig. 2a) and
SCARB1 (Fig. 2b) mRNA expression than controls. In
contrast, CD36 mRNA expression was downregulated inand clinicopathological parameters
Model 2
p-value OR (95 % CI) p-value
0.018* 2.084 (1.092-3.978) 0.037*
0.329 0.675 (0.282-1.617) 0.378
0.709 0.999 (0.716-1.394) 0.997
0.249 0.808 (0.561-1.164) 0.808
0.629 1.098 (0.715-1.685) 0.670
0.013* 1.906 (1.118-3.249) 0.018*
0.015* 1.746 (1.078-2.829) 0.024*
Fig. 2 (See legend on next page.)
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Fig. 2 Analysis of LDLR, SCARB1 and CD36 mRNA expression in control and CE-rich groups and correlation with intratumor CE-content. Real-time
PCR analysis of LDLR, SCARB1 and CD36 mRNA expression. Data were processed by especially designed software based on the Ct value of each
sample and normalized to 18srRNA. Bar graphs showing medians (interquartile ranges) of normalized values of LDLR (a), SCARB1 (b) and CD36 (c)
mRNA expression in control (N = 20) and CE-rich (N = 10) groups. Correlations between intratumor CE content and LDLR (d), SCARB1 (e) and
CD36 (f) mRNA expression in breast tumors
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tically significant correlation between LDLR expression
levels and intratumor CE content was observed (Fig. 2d).
The correlation between intratumor CE content and
LDLR (positive) (Fig. 2e) or CD36 (negative) (Fig. 2f ) did
not reach statistical significance. In line with real time
PCR analysis, western blot analysis showed that protein
levels or LDLR (Fig. 3a and b) and SCARB1 (Fig. 3a and
c) were significantly higher in CE-rich breast tumors
than in controls. Real time PCR experiments also
showed higher ACAT1 mRNA expression levels in CE-
rich tumors than in the control group (Fig. 4a). ACAT
mRNA expression was positively correlated with LDLR
(Fig. 4b) and SCARB1 (Fig. 4c) mRNA expression. There
were no differences in the expression of lipid mediators
implicated in cholesterol synthesis (HMG-CoAR), choles-
terol management (CAV1, LXR-α, SREBP1 and SREBP2)
and cholesterol efflux (ABCA1) between groups. NoFig. 3 Analysis of LDLR and SR-BI protein levels in control and CE-rich grou
protein levels in breast tumors (a). Ponceau staining was used as loading c
LDLR (b) and SCARB1 (c) protein levels in control (N = 20) and CE-rich (N =differences were observed in invasiveness markers
(MMP2, MMP9, TIMP and CTSS) between groups
(Additional file 1: Table S2).
Discussion
This investigation demonstrated an important association
of intratumor cholesteryl ester (CE) accumulation with
tumor proliferation but not with invasiveness. We also
found that mechanisms potentially involved in intratu-
moral CE accumulation may be lipid internalization
through the overexpression of LDLR and SCARB1 recep-
tors and cholesterol esterification through the upregula-
tion of ACAT1 enzyme.
Group-wise comparisons, linear regression and logistic
regression models showed that human breast tumors in
the highest tertile of CE content, CE-rich tumors, were
intimately associated with higher breast tumor aggressive
potential. Our results also showed a close relationshipps. Representative Western blot analysis showing LDLR and SR-BI
ontrol. Bar graphs showing medians (interquartile ranges) of normalized
10) groups
Fig. 4 Analysis of ACAT mRNA expression in control and CE-rich groups and its correlation with intratumor CE-content. Real-time PCR analysis of
ACAT mRNA expression (a). Data were processed using a specially designed software based on Ct value of each sample and normalized to
18srRNA. Bar graphs showing medians (interquartile ranges) of normalized values of ACAT mRNA expression in control (N = 20) and CE-rich
(N = 10) groups. Correlations between ACAT and LDLR mRNA expression (b) and between ACAT and SCARB1 (c) mRNA expression in
breast tumors
de Gonzalo-Calvo et al. BMC Cancer  (2015) 15:460 Page 10 of 13between intratumoral CE accumulation and Ki-67, a well-
known marker of proliferation, associated with shorter
disease-free survival and overall survival and more fre-
quent tumor recurrence [32]. In addition, we found that
intratumoral CE accumulation was intimately associated
with higher tumor necrosis, an independent prognostic
variable of progression-free and cancer-specific survival
[33]. Our data support a close link between breast intratu-
mor CE accumulation and tumor proliferation, indicating
that intratumor CE accumulation is associated with poor
clinical outcome of patients with breast cancer. These
results are in line with previous findings showing anassociation between intratumor neutral lipids and tumor
malignancy [20, 34]. At present we could only speculate
about the role of CE in tumor proliferation and aggres-
sive potential; however, it has been proposed that stored
CE may reduce the energetically costly lipid synthesis,
increase membrane synthesis and rigidity, and induce a
pro-tumorigenic signaling, all mechanisms linked to the
malignancy of breast cancer [2, 18, 20].
Results for the present study showed a tight correl-
ation between intratumor CE accumulation and LDLR
expression and that both LDLR mRNA and protein
levels were significantly elevated in CE-rich breast
de Gonzalo-Calvo et al. BMC Cancer  (2015) 15:460 Page 11 of 13carcinomas. These results suggest that LDLR overex-
pression facilitates an exacerbated LDL-cholesterol up-
take by breast tumor cells. A crucial question is why
LDLR, a receptor that is usually downregulated by intra-
cellular cholesterol [35], remains upregulated despite el-
evated intratumor CE levels. It has been proposed that
increased ACAT activity, may contribute to cholesterol
removal from endoplasmic reticulum by promoting the
cholesterol esterification rate [36]. Cholesterol of the
endoplasmic reticulum represses the activation of
SREBPs, key transcription factors involved in the posi-
tive modulation of LDLR and other lipogenic genes such
as HMG-CoA reductase. Our results show that the ex-
pression of SREBP-1, SREBP-2, LDLR or HMG-CoA re-
ductase was not significantly reduced in breast CE-rich
tumors in which ACAT was upregulated. These results
indicate that intracellular cholesterol could not repress
SREBP or SREBP-modulated genes because cholesterol
is rapidly esterified through ACAT in tumor cells. Con-
sistently, we found a close and direct correlation be-
tween ACAT and LDLR overexpression in breast
tumors. Therefore, as previously suggested in breast can-
cer cell lines [36], overexpression of ACAT in human
breast cancer maintains low endoplasmic reticulum
cholesterol levels, thereby allowing LDL cholesterol to
enter the tumor. Our results show that, both LDLR and
ACAT overexpression contribute to tumor malignancy
in breast cancer patients by promoting intratumoral CE
accumulation. Our data are in agreement with previous
in vitro studies highlighting the pivotal role of LDLR
[36], and ACAT [19, 37] overexpression in massive choles-
terol internalization, in particular in ER- breast cell lines.
Here, we also show a significant upregulation of another
lipoprotein receptor, SCARB1, in human CE-rich breast
carcinomas. SCARB1 is a cell-surface glycoprotein thatFig. 5 Representative scheme showing potential mechanisms involved in i
with breast cancer aggressive potentialmediates LDL-CE [38], and HDL-CE [39], selective up-
take. According to our results, SCARB1 levels, similar
to LDLR levels, are significantly elevated in CE-rich
breast carcinomas and significantly correlated with ACAT
expression. Moreover, SCARB1 has been reportedly up-
regulated by hypercholesterolemia in a breast cancer mice
model [40]. Taken together, these results suggest that
SCARB1, besides LDLR, may actively contribute to hu-
man breast tumor CE accumulation and aggressive poten-
tial. In line with this, it has been reported that SR-BI
knockdown inhibits cellular proliferation in in vitro [10],
and in vivo breast cancer models [18]. These results sug-
gest that LDLR and SCARB1 overexpression combined
with ACAT overexpression are key mechanisms for intra-
tumor CE accumulation in human breast carcinomas.
Differently to LDLR and SCARB1 upregulation, CD36
mRNA expression was significantly downregulated in
more aggressive CE-rich breast cancer tumors. This is
an interesting finding since the loss of CD36 has been
proposed as one of the early events in breast carcinogen-
esis [41]. CD36 is lower in high density breast tissue
than in normal density tissue [42]. Notably, normal adja-
cent tissue from TN tumors exhibited significantly lower
CD36 expression levels than ER+ or Her-2 tumors, sug-
gesting that low expression levels of CD36 may predis-
pose to TN tumors and to poor disease outcomes [42].
Despite the capacity of CD36 to bind native and modi-
fied lipoproteins [43], CD36 does not seem to contribute
to intratumor CE accumulation in breast cancer. Further
studies are required to know why CD36 is downregu-
lated in CE-rich breast cancer carcinomas.
Previous in vitro studies showed that modified lipopro-
teins induced breast tumor proliferation, migration and
invasiveness [12, 13, 44]. Blockade of CE entry and bio-
synthesis led to decreased cell migration [18, 36]. Inntratumor CE accumulation in breast cancer patients and their relation
de Gonzalo-Calvo et al. BMC Cancer  (2015) 15:460 Page 12 of 13contrast, previous results from our group showed that
intracellular CE accumulation decreased human vascular
cell migration even in the presence of the hypoxic
stimulus [45, 46]. In line with the negative effect of intra-
cellular CE content on vascular cell migration, we could
not detect a relation of intratumoral CE accumulation
with migration and invasion markers (MMP9, MMP2,
TIMP and CTSS) in breast tumors, nor with clinicopath-
ological characteristics of invasion (TNM stage, number
of lymph nodes affected, and vascular invasion). Further
investigation is required to explain why intratumor CE do
not show association with invasiveness despite CE-rich
tumors have a high aggressive potential,
Lipid profiling classifications have the advantage over
molecular classifications which allows better stratifica-
tion of breast cancer malignancy [47]. Our study shows
that intratumor CE accumulation is a good indicator of
human breast cancer proliferation. We suggest thus that
intratumor CE would be a marker of aggressive potential
after mastectomy or lumpectomy and that cholesterol
internalization and esterification mediators are potential
targets to counteract intratumor CE accumulation (sum-
marized in Fig. 5).
A larger study sample would have been desirable and
our findings should be reproduced in a significantly lar-
ger cohort. A detailed description of cause-effect mecha-
nisms cannot be provided when working with human
samples from breast cancer tumors.
Conclusion
In conclusion, our results highlight intratumor CE accu-
mulation as a potential indicator of proliferation in hu-
man breast cancer. LDLR and SCARB1 overexpression
besides ACAT1 activation may be crucial players causing
intratumoral CE accumulation. These results thus open
the door to new anticancer therapeutic strategies.
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